MedTrace Logo

GSK618334 Repeat Dose Study

NCT01036061 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-06-22

No results posted yet for this study

Summary

The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.

Conditions

  • Substance Dependence

Interventions

DRUG

GSK618334 Low Dose

GSK618334 low dose

DRUG

GSK618334 PET subjects

PET subjects

DRUG

GSK618334 Medium Dose

Medium Dose

DRUG

GSK618334 High Dose

GSK618334 High Dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-28
Primary Completion
2010-02-17
Completion
2010-02-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01036061 on ClinicalTrials.gov